Dec 12, 2019: U.S. Food and Drug Administration (FDA) has approved Pfizer’s XELJANZ ® XR (tofacitinib) extended-release 11 mg and 22 mg tablets for the once-daily treatment of adult patients with moderately to severely active ulcerative colitis (UC), after an inadequate response or intolerance to TNF blockers.
Ulcerative colitis is a chronic inflammatory disease that can significantly affect a patient’s quality of life and be emotionally oppressive due to symptoms, flares and complications.
XELJANZ/XELJANZ XR, indicated for the treatment of adult patients suffering with moderate to severe active UC, who have had an inadequate response or who are intolerant to TNF blockers.
XELJANZ ® (tofacitinib) is approved for adult patients with three indications: moderately to severely active rheumatoid arthritis (RA) after methotrexate failure, active psoriatic arthritis (PsA) after disease modifying antirheumatic drug (DMARD) failure and moderate to severe active ulcerative colitis (UC) after tumor necrosis factor inhibitor (TNFi) failure. https://www.oaoa.com/news/business/article_0f2d0780-5ba9-5766-b3ff-7a4b0317b5bd.html
